Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Boehringer Ingelheim Pharmaceuticals |
---|---|
Information provided by: | Boehringer Ingelheim Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00281593 |
To demonstrate that Micardis and Altace when used together are more effective at lowering blood pressure.
Condition | Intervention | Phase |
---|---|---|
Hypertension |
Drug: Telmisartan Drug: Ramipril |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment |
Official Title: | A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, 3x4 Factorial Design Trial to Evaluate Telmisartan 20 and 80 mg Tablets in Combination With Ramipril 1.25, 10, and 20 mg Capsules After Eight Weeks of Treatment in Patients With Stage I or II Hypertension, With an ABPM Sub-Study |
Enrollment: | 1354 |
Study Start Date: | April 2006 |
Primary Completion Date: | April 2007 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study Chair: | Boehringer Ingelheim | Boehringer Ingelheim Pharmaceuticals |
Responsible Party: | Boehringer Ingelheim ( Boehringer Ingelheim, Study Chair ) |
Study ID Numbers: | 1236.1 |
Study First Received: | January 24, 2006 |
Last Updated: | December 15, 2008 |
ClinicalTrials.gov Identifier: | NCT00281593 |
Health Authority: | Argentina: A.N.M.A.T. (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica); United States: Food and Drug Administration |
Vascular Diseases Telmisartan Angiotensin II Ramipril Hypertension |
Angiotensin II Type 1 Receptor Blockers Molecular Mechanisms of Pharmacological Action Therapeutic Uses Angiotensin-Converting Enzyme Inhibitors Enzyme Inhibitors |
Cardiovascular Diseases Cardiovascular Agents Antihypertensive Agents Pharmacologic Actions Protease Inhibitors |